CBC Group

CBC Group

CBC Group was founded in Singapore in 2014 by Weijian Shan, the former TPG partner who famously led Newbridge Capital's landmark acquisition of Korea First Bank. Shan structured CBC as an independent, healthcare-only investment firm from day one, drawing on his experience bridging Wall Street discipline and Asian dealmaking. The firm is not a family office or a generalist private equity shop; its entire mandate revolves around controlling stakes in pharmaceutical, biotech, medical device, and healthcare-services companies across Greater China and broader Asia. CBC runs a concentrated buyout and growth-equity strategy across three primary verticals: pharmaceuticals and biotech, medical devices, and healthcare services. The firm writes equity checks for control and significant-minority positions, typically in the range of $50 million to $300 million per deal, and holds assets for five to seven years. Confirmed portfolio positions include Hasten Biopharmaceutical, a China-focused specialty pharma platform assembled via bolt-on acquisitions, and R-Bridge Healthcare, a specialty pharmaceutical and medical-device distribution business serving mainland China. CBC also raised at least one dedicated credit vehicle, CBC Credit Opportunities Fund, to provide debt financing to healthcare companies across the region. The firm operates from its Singapore headquarters with additional offices in Beijing, Shanghai, and Hong Kong. In June 2023, CBC closed its fourth flagship private equity fund, CBC Fund IV, though exact figures were not publicly disclosed. Shan, who chairs the investment committee, has built a team spanning investment professionals, operating partners, and in-house clinical advisors — a structure designed to diligence drug pipelines and regulatory pathways with the same rigor as financial models. The firm also maintains an executive-in-residence program to place seasoned operators into portfolio companies. CBC's structural differentiator is its sector concentration inside a region where specialist buyout firms remain rare. Most healthcare investing in Asia flows through generalist funds or corporate venture arms; CBC's single-sector mandate gives it proprietary sourcing advantages with founder-entrepreneurs and hospital groups who prefer a knowledgeable, long-term capital partner. The firm also cross-leverages its portfolio by facilitating distribution partnerships and licensing deals between its drug-platform companies and its medical-device assets, creating operational synergies that a financial sponsor tracking multiple industries cannot replicate.